Navigation Links
For Breast Cancer Treatment, an Agent That Can Achieve an Overall Survival Benefit Would Pose the Greatest Challenge to Avastin's Dominance in Europe
Date:12/15/2009

WALTHAM, Mass., Dec. 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an overall survival benefit would be the most influential factor for three-quarters of surveyed European oncologists in their decision to prescribe a novel agent ahead of Avastin for the treatment of breast cancer.

The new Special European Physician & Payer Forum report entitled European Trends in Targeted Therapies in Breast Cancer: A Clinician and Payer Perspective on the Current and Future Uptake finds that, despite not having a HER2 (human epidermal growth factor receptor-2) status label restriction in Europe, most surveyed oncologists reserve Avastin for HER2-negative patients, particularly for patients with triple negative breast cancer. Avastin is at risk of losing significant patient share to Sanofi-Aventis' novel agent BSI-201, which is expected to be approved for triple negative breast cancer on the basis of an improvement in overall survival.

According to the report, in the surveyed European countries where Avastin is reimbursed, Avastin is used in between 16 percent (in Italy) and 38 percent (in France) of first-line metastatic breast cancer patients and between 8 percent (in Italy) and 27 percent (in France) of second-line metastatic breast cancer patients. Through 2010, Avastin's patient share will increase to between 25 percent (in Italy and Spain) and 35 percent (in France) in the first-line treatment setting and between 17 percent (in Italy) and 36 percent (in France) in the second-line. This equates to a potential 30 percent increase in Avastin sales over the next 12 months.

The report also finds that reimbursement of targeted therapies for breast cancer varies significantly between the European countries surveyed.

"Among the four major European markets that reimburse Avastin--Germany, France, Italy a
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
7. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
8. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
11. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 Research and Markets has announced ... report to their offering. Animal vaccines ... Animal vaccines are generally prepared from weakened or dead microbes ... state. Some of the animal vaccines are also formulated using ... or toxic components. These components act as ...
(Date:9/16/2014)... 16, 2014  Denovo Biopharma, LLC, today announced ... drug, from Eli Lilly and Company (NYSE:  LLY). ... commercialize enzastaurin globally, including transfer of all intellectual ... Lilly developed enzastaurin in a variety ... 3 clinical trials for diffuse large B-cell lymphoma ...
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
Breaking Medicine Technology:Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4
... 2011  GP Strategies Corporation (NYSE: GPX ), ... GP Strategies Corporation with and into its ... company structure. General Physics, which is the sole operating ... corporation and will be renamed GP Strategies Corporation when ...
... BOWIE, Md., Dec. 15, 2011  MedAssurant, Inc., ... today announced that Healthcare Partners, IPA (HCPIPA), ... associations (IPA) in the Northeast, has selected ... (CARA™)  solutions to proactively identify gaps in ...
Cached Medicine Technology:GP Strategies Shareholders Approve Elimination of Holding Company Structure and Renaming of General Physics Corporation 2GP Strategies Shareholders Approve Elimination of Holding Company Structure and Renaming of General Physics Corporation 3Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 2Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 3
(Date:9/16/2014)... 16, 2014 Holganix, an elite member ... growing companies in the country, produces an organic Bionutritional ... health-care by naturally decreasing disease and insect damage though ... that it will hold its third annual Bionutritional Summit ... 22, 2014 from 1:00 P.M. through 6:00 P.M., the ...
(Date:9/16/2014)... Recently, iFitDress.com, one of the most famous ... one shoulder evening gown collection. According to the company’s ... discounted rates (up to 69% off) at present. Additionally, all ... , “I am a frequent caller of your site. I ... dress, I feel quite happy. All items are of good ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, 2014 ... human papillomavirus (HPV), which is linked to the risk of ... that testing urine for HPV has good accuracy when compared ... lead researcher Dr. Neha Pathak. She is a resident in ... of London, England. The test could be done at ...
(Date:9/16/2014)... These new programs allow those who haven’t owned a home ... in a 0% interest free, 2nd down payment assistance mortgage ... programs, are listed on their private website. The $10,000 does ... move out of the property. The down payment assistance 2nd ... monthly payments paid by the Borrower. The money is paid ...
(Date:9/16/2014)... September 14, 2014 A new study ... branch (SB) stenting of true coronary bifurcation lesions ... care. The DKCRUSH-VI clinical trial is the first ... , Findings were reported today at the 26th ... by the Cardiovascular Research Foundation (CRF), TCT is ...
Breaking Medicine News(10 mins):Health News:Holganix Holds 3rd Annual Bionutrional Summit in Louisville, Kentucky 2Health News:iFitDress.com: One Shoulder Evening Gown Collection Unveiled Online 2Health News:Urine Test for HPV Works Well, Analysis Finds 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 3Health News:Results of DKCRUSH-VI trial reported at TCT 2014 2
... Justice Department,today announced that it has reached a ... headquartered in Southfield, Mich., under the,Americans with Disabilities ... Clinic refused to serve a prospective client because ... today,s agreement, Medical Weight Loss Clinic will,provide training ...
... more than 40 percent of widowers in that country whose ... they were either never told that their spouse,s cancer was ... of her life. Eighty-six percent of widowers believed next-of-kin should ... 71 percent of the men who did not recall being ...
... Preventive Medicine, (http://www.USPreventiveMedicine.com ) the leader in disease ... its campaign to make the,United States a healthier ... Pediatrics, which this week called for children to ... the "Healthiest Nation Campaign," a program aimed,at placing ...
... in Oxygen Orders, Lack of,Trained Technicians, ARLINGTON, ... program for durable medical equipment has created,concern and ... medical equipment providers across the country since it,was ... The bidding program has triggered widespread disruptions ...
... Chicago is one of 11 centers in the United ... Clinical Islet Transplant Consortium funded by the National Institutes ... to test new approaches to islet transplantation that may ... adults with difficult-to-control type 1 diabetes. , Patients with ...
... team will give the men we serve a distinct advantage on, ... ... Directors, DETROIT, July 8 The Mariners Inn shelter ... executive officer and David Sampson as chief operating officer., "Both Jim and ...
Cached Medicine News:Health News:Justice Department Reaches Settlement Agreement With Medical Weight Loss Clinic 2Health News:Study finds that significant proportion of men told wife's cancer was incurable late or not at all 2Health News:U.S. Preventive Medicine Applauds Leading Health Organizations for Disease Prevention Platforms 2Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 2Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 3Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 4Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 5Health News:UIC in NIH-funded islet transplantation study for type 1 diabetes 2Health News:Mariners Inn Announces New Executive Leadership 2
The GII titanium anchor with nitinol arcs is used for soft tissue reattachment to bone. The GII's small size, high pull-out strength and wide range of clinical applications make it the anchor used by...
... greater definition than a standard Galilean ... The Hi-Res five element system provides ... lightweight system., ,Order frame separately., ,Keeler ... in a soft carrying case and ...
The Nevyas Drape Support is the simple and inexpensive way to establish a zone of comfort for your patients during ophthalmic surgery which requires draping over the nose and mouth. Packaged in sets ...
... Wristrest has become an important standard in busy ... encircles the patient's head and supports arms and ... easy draping especially when fluids are collected. The ... way for easy patient transfer on and off ...
Medicine Products: